Targovax ASA logo

TRVX - Targovax ASA News Story

NOK6.34 0.0  0.0%

Last Trade - 11:01am

Sector
Healthcare
Size
Micro Cap
Market Cap £41.6m
Enterprise Value £35.8m
Revenue £221k
Position in Universe 1021st / 1792

BRIEF-Targovax Releases Update For Mesothelioma Trial Combining ONCOS-102 And Chemotherapy

Mon 4th May, 2020 6:06am
May 4 (Reuters) - Targovax ASA  TRVX.OL :
    * TARGOVAX RELEASES UPDATE FOR MESOTHELIOMA TRIAL COMBINING
ONCOS-102 AND CHEMOTHERAPY
    * IMMUNE ACTIVATION IS FURTHER VALIDATED IN ONCOS-102
TREATED
GROUP
    * FIRST LINE MESOTHELIOMA REMAINS FOCUS FOR NEXT PHASE OF
DEVELOPMENT

Source text for Eikon:  ID:nWkrb5HT2N 
Further company coverage:  TRVX.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.